The adrenergic-fatty acid load in heart failure

Area of Science:

• Cardiology
• Metabolic Medicine
• Pharmacology

Background:

• Heart failure (HF) is linked to a hyperadrenergic state, elevating plasma free fatty acids (FFAs).
• Elevated FFAs contribute to impaired glucose metabolism and insulin resistance via mitochondrial dysfunction and oxidative stress.
• This metabolic derangement is a key factor in HF progression.

Purpose of the Study:

• To explore the hypothesis that a reactive hyperadrenergic state in HF increases FFAs, leading to insulin resistance.
• To outline therapeutic strategies targeting metabolic dysfunction in HF.
• To review existing and potential pharmacological interventions for HF metabolic therapy.

Main Methods:

• Review of existing literature on HF pathophysiology and metabolic interventions.
• Analysis of proposed therapeutic aims: decreasing hyperadrenergic drive, inhibiting lipotoxicity/glucotoxicity, and increasing glucose uptake.
• Evaluation of pharmacological agents like beta-blockers, trimetazidine, perhexiline, metformin, ranolazine, insulin, incretins, and others.

Main Results:

• Exercise is the only intervention with mortality reduction data. Trimetazidine shows metabolic and clinical benefits with minimal side effects, though large outcome trials are pending.
• Trimetazidine's action may occur significantly outside the heart.
• Ranolazine and insulin require further investigation in human HF.

Conclusions:

• Metabolic therapies targeting FFAs and glucose metabolism are crucial for managing HF.
• Trimetazidine demonstrates significant potential, warranting further outcome studies.
• Future HF treatments may involve novel agents modulating fatty acid oxidation and cellular signaling pathways.